Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 807

1.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

2.

Intravesical gemcitabine for non-muscle invasive bladder cancer.

Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD009294. doi: 10.1002/14651858.CD009294.pub2. Review.

PMID:
22259002
3.
4.

Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.

Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M.

Cochrane Database Syst Rev. 2003;(3):CD003231. Review. Update in: Cochrane Database Syst Rev. 2015;11:CD003231.

PMID:
12917955
5.

Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.

Houghton BB, Chalasani V, Hayne D, Grimison P, Brown CS, Patel MI, Davis ID, Stockler MR.

BJU Int. 2013 May;111(6):977-83. doi: 10.1111/j.1464-410X.2012.11390.x. Review.

6.

Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.

Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW.

J Urol. 2013 Nov;190(5):1686-91. doi: 10.1016/j.juro.2013.04.120.

PMID:
23665400
7.

Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.

Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K, Yue ZJ, Tian JQ.

Cochrane Database Syst Rev. 2011 May 11;(5):CD006885. doi: 10.1002/14651858.CD006885.pub2. Review.

PMID:
21563157
8.

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA.

Eur Urol. 2009 Aug;56(2):247-56. doi: 10.1016/j.eururo.2009.04.038.

PMID:
19409692
9.

Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.

Böhle A, Leyh H, Frei C, Kühn M, Tschada R, Pottek T, Wagner W, Knispel HH, von Pokrzywnitzki W, Zorlu F, Helsberg K, Lübben B, Soldatenkova V, Stoffregen C, Büttner H; S274 Study Group..

Eur Urol. 2009 Sep;56(3):495-503. doi: 10.1016/j.eururo.2009.06.010.

PMID:
19560257
10.

Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.

Shelley M, Cleves A, Wilt TJ, Mason M.

Cochrane Database Syst Rev. 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. Review.

PMID:
21491413
11.

Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.

Gandhi NM, Morales A, Lamm DL.

BJU Int. 2013 Aug;112(3):288-97. doi: 10.1111/j.1464-410X.2012.11754.x. Review.

12.

Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.

Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M.

Cochrane Database Syst Rev. 2000;(4):CD001986. Review.

PMID:
11034738
13.

The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.

Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F.

J Urol. 2013 Sep;190(3):857-62. doi: 10.1016/j.juro.2013.03.097.

PMID:
23545101
14.

Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.

Shelley MD, Cleves A, Wilt TJ, Mason MD.

BJU Int. 2011 Jul;108(2):168-79. doi: 10.1111/j.1464-410X.2011.10341.x. Review.

15.

Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.

Nielsen ME, Smith AB, Pruthi RS, Guzzo TJ, Amiel G, Shore N, Lotan Y.

BJU Int. 2012 Oct;110(7):967-72. doi: 10.1111/j.1464-410X.2012.11060.x.

16.

The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.

Gontero P, Bohle A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, Witjes F.

Eur Urol. 2010 Mar;57(3):410-29. doi: 10.1016/j.eururo.2009.11.023. Review.

PMID:
19969411
17.

Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial.

Perdonà S, Di Lorenzo G, Cantiello F, Damiano R, De Sio M, Masala D, Bruni G, Gallo L, Federico P, Quattrone C, Pizzuti M, Autorino R.

Anticancer Drugs. 2010 Jan;21(1):101-6. doi: 10.1097/CAD.0b013e3283324d83.

PMID:
19858710
18.
19.

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

Lamm D, Brausi M, O'Donnell MA, Witjes JA.

Urol Oncol. 2014 Jan;32(1):35.e21-30. doi: 10.1016/j.urolonc.2013.02.010. Review.

PMID:
23628309
20.

Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.

Yates DR, Brausi MA, Catto JW, Dalbagni G, Rouprêt M, Shariat SF, Sylvester RJ, Witjes JA, Zlotta AR, Palou-Redorta J.

Eur Urol. 2012 Dec;62(6):1088-96. doi: 10.1016/j.eururo.2012.08.055. Review.

PMID:
22959049
Items per page

Supplemental Content

Support Center